A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the
efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus
trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and
have not received systemic anticancer therapy for advanced disease.